SCHEMBL6494039

SCHEMBL6494039

COc1ccc(Cn2c(C)nc3ccc(C(=O)NS(=O)(=O)c4ccc(C)cc4)nc32)c(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 3/20 0.45
FLT4 P35916 3/20 0.45
KDR P35968 3/20 0.45
PTGS2 P35354 2/20 0.43
PTGS1 P23219 1/20 0.43
AKR1C3 P42330 2/20 0.42
AKR1C2 P52895 2/20 0.42
PPARG P37231 1/20 0.40
EGFR P00533 2/20 0.40
MAPT P10636 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
FBP1 P09467 2/20 0.39
PTGES O14684 1/20 0.38
ALOX5 P09917 1/20 0.38
P4HTM Q9NXG6 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6301497 0.93 FLT1 (0.43) FLT1FLT4KDRPTGS2PTGS1
SCHEMBL6299947 0.92 PTGS2 (0.40) FLT1FLT4KDRPTGS2PTGS1
SCHEMBL6502291 0.92 PTGS2 (0.44) FLT1FLT4KDRPTGS2PTGS1
SCHEMBL6384564 0.92 PTGS2 (0.41) FLT1FLT4KDRPTGS2PTGS1
SCHEMBL6298794 0.90 PPARG (0.41) FLT1FLT4KDRPTGS2PTGS1
SCHEMBL6491654 0.90 PPARG (0.45) FLT1FLT4KDRPTGS2PTGS1
SCHEMBL6299390 0.90 FLT1 (0.50) FLT1FLT4KDRPTGS2PTGS1
SCHEMBL6300811 0.89 PPARG (0.45) FLT1FLT4KDRPTGS2PTGS1
SCHEMBL6499681 0.88 PPARG (0.45) FLT1FLT4KDRPTGS2PTGS1
SCHEMBL6299853 0.88 MCL1 (0.43) PTGS2PTGS1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US claimed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US claimed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP claimed
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A FLT1 1514/4885FLT4 2482/4885KDR 2355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.